Table 2.
Change from baseline in Hb and iron-related factors when switching from ESA to HIF-PHI in HD patients.
| Roxadustat | Daprodustat | Vadadustat | Enarodustat | Molidustat | ||
|---|---|---|---|---|---|---|
| Starting dose (/day) | Same as in NDD patients |
Same as in NDD patients |
Same as in NDD patients |
Once daily 4 mg |
Once daily 75 mg |
|
| Maintenance dose (/day) | Same as in NDD patients | Same as in NDD patients | ||||
| Wk 4 | Hb | ↑ | ↓ | ↓ | ↑ | ↓ |
| s-ferritin | ↓ | ↑ | ↑ | ↓ | ↑ | |
| s-iron | ↓ | ↑ | - | ↑ | ↑ | |
| TIBC | ↑ | ↑ | ↑ | ↑ | ↑ | |
| TSAT | ↓ | ↑ | ↑ | ↑ | ↑ | |
| Hepcidin | ↓ | ↓ | ↑ | ↓ | - | |
| transferrin | ↑ | - | - | - | - | |
| Wk 52 (24 #) |
s-ferritin | ↓ | ↓ | → | ↑# | ↑ |
| s-iron | → | ↑ | - | ↓# | ↑ | |
| TIBC | ↑ | ↑ | ↑ | ↑# | → | |
| TSAT | ↓ | → | → | →# | ↑ | |
| Hepcidin | ↓ | ↓ | ↓ | ↓# | ↓ | |
| transferrin | ↑ | ↑ | - | - | - | |
| Mean or median # Dose (mg/day) |
74.1 (43.6) | ERI < 4.79; 4.0 # ERI (≥4.79, <8.0); 6.0 # ERI ≥ 8.0; 6.0 # |
367.65 | 4.26 | 79.02 | |
| Evaluation period | wk 50 | wk 40–52 | wk 52 | wk 20–24 | wk 0–50 | |
| Ref | 121 | 123 | 125 | 127 | 130 | |
ERI, erythropoiesis-stimulating agent resistance index; Hb, hemoglobin; NDD, non-dialysis dependent; TIBC, total iron-binding capacity, which reflects transferrin levels; TSAT, transferrin saturation; #, Evaluation at 24 weeks.